1 / 35

2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano

2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano. CLL12: Phase 3 Trial of Ibrutinib vs Placebo in Asymptomatic, Untreated Early-Stage CLL. RESONATE-2: Phase 3 Trial of Ibrutinib vs Chlorambucil in Patients Age ≥ 65 With Untreated CLL.

westd
Download Presentation

2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano

  2. CLL12: Phase 3 Trial of Ibrutinib vs Placebo in Asymptomatic, Untreated Early-Stage CLL

  3. RESONATE-2: Phase 3 Trial of Ibrutinib vs Chlorambucil in Patients Age ≥ 65 With Untreated CLL

  4. CLL14: Phase 3 Trial of Venetoclax + Obinutuzumab in Patients With CLL and Coexisting Conditions

  5. ASCEND: Phase 3 Trial of Acalabrutinib vs IR or BR in R/R CLL

  6. Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With R/R CLL

  7. 2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano

  8. CHRONOS-1: Single-Agent Copanlisib Long-Term Follow-Up in Patients With R/R FL

  9. Phase 1b/2 Trial of Polatuzumab Vedotin + Obinutuzumab and Lenalidomide in Patients With R/R FL

  10. Phase 1b Study of PI3Kδ Inhibitor ME-401 +/- Rituximab: Results in Patients With R/R FL

  11. AUGMENT: Phase 3 Trial of Lenalidomide + Rituximab vs Rituximab in R/R Indolent NHL

  12. 2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano

  13. Phase 2 Trial of Ibrutinib + Rituximab in Elderly Patients (> 65 Years) With Previously Untreated MCL

  14. Phase 3 Study of Acalabrutinib + BR in Elderly (Aged ≥ 65 Years) Patients With Treatment-Naive MCL

  15. LYMA-101: Phase 2 Study of Obi + DHAP Followed by ASCT + Obi Maintenance in Untreated MCL

  16. TRANSCEND NHL 001: Phase 1 Study of Liso-Cel in R/R B-Cell NHL: Outcomes in R/R MCL

  17. MANTLE-FIRST: Outcomes in 258 Patients With R/R MCL With POD or First Relapse After HDAC +/- ASCT

  18. 2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano

  19. HOVON-Nordic Phase 3 Trial of Rituximab Maintenance for Patients With DLBCL in CR1

  20. CAVALLI: Phase 2 Study of Venetoclax + R-CHOP in Bcl2+ DLBCL

  21. ECOG-ACRIN1412: Phase 2 Study of R2CHOP vs R-CHOP in Previously Untreated DLBCL

  22. ROBUST: Phase 3 trial of R2-CHOP vs Placebo/R-CHOP in Previously Untreated ABC-Type DLBCL

  23. Smart Start: R, Len, Ibr (RLI) Prior to CHOP or EPOCH for Patients With Previously Untreated DLBCL

  24. Immune-Related Conditions in DLBCL Survivors

  25. 2019 Lymphoma Data Highlights from Chicago, Amsterdam, and Lugano

  26. CHRONOS-1: Copanlisib in R/R MZL

  27. Cohort of UNITY-NHL: Umbralisib in R/R MZL

  28. Ibrutinib Monotherapy in Previously Treated Waldenstrom Macroglobulinemia

  29. PROs From iNNOVATE: Waldenstrom Macroglobulinemia Treated With Ibr-R

  30. Abbreviations

  31. Abbreviations (cont)

  32. Abbreviations (cont)

  33. Abbreviations (cont)

  34. Abbreviations (cont)

  35. Abbreviations (cont)

More Related